Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 8:52 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III L.P. | 4,824,731 14.000% |
1,251,017 (+35.01%) |
Filing |
| 2023-12-28 4:16 pm Purchase |
2023-12-26 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III L.P. | 3,573,714 10.300% |
657,047 (+22.53%) |
Filing |
| 2023-01-09 4:06 pm Purchase |
2022-12-28 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III L.P. | 2,916,667 8.600% |
2,916,667 (New Position) |
Filing |